Pharmaceuticals China

China Retinal Disease Drugs Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

China Retinal Disease Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

China · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $1.31 Bn Placeholder estimate
Estimate 2025 $1.41 Bn 8.4% of the global market
Projected 2034 $2.74 Bn 93.3% Adds $1.32 Bn over 9 forecast years
CAGR 2025–2034 7.6% Faster than 27% of 180 Pharmaceuticals markets here
Key players 5
  • China is 8.4% of the global market.
  • In APAC, the largest is China (this report) at $1.41 Bn.
  • Fastest growing: India at 8.7% a year.
  • China ranks 1st of 10 by size in APAC.

Market size projection

China

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.32 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Retinal Disease Drugs Market market size by year, China
YearMarket sizeChange that yearSince 2025
2024 (estimate) $1.31 Bn — —
2025 (base) $1.41 Bn +$99.9 Mn —
2026 (forecast) $1.52 Bn +$107.5 Mn +7.6%
2027 (forecast) $1.64 Bn +$115.7 Mn +15.8%
2028 (forecast) $1.76 Bn +$124.5 Mn +24.6%
2029 (forecast) $1.90 Bn +$134.0 Mn +34%
2030 (forecast) $2.04 Bn +$144.1 Mn +44.2%
2031 (forecast) $2.20 Bn +$155.1 Mn +55.2%
2032 (forecast) $2.36 Bn +$166.9 Mn +67%
2033 (forecast) $2.54 Bn +$179.6 Mn +79.7%
2034 (forecast) $2.74 Bn +$193.2 Mn +93.3%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

China Retinal Disease Drugs Market Analysis at a glance
Market size, 2025$1.41 Bn placeholder estimate
Forecast, 2034$2.74 Bn placeholder estimate
Growth (CAGR), 2025–20347.6% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug, indication and end user (see all)
Key playersRegeneron Pharmaceuticals, Roche, Bayer AG, Novartis AG, Samsung Bioepis (see all)
Regulator in ChinaNMPASource: National Medical Products Administration. Checked 14 Nov 2026.
Active clinical trials55 in ChinaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The China Retinal Disease Drugs Market Analysis Executive Summary

Retinal disease drugs, mostly anti-VEGF injections, treat wet macular degeneration and diabetic eye disease.

Key segments of the retinal Disease Drugs market include drug (Aflibercept, Faricimab and Ranibizumab) and indication (Wet AMD, Diabetic Macular Edema and Retinal Vein Occlusion).

Bar chart: China Retinal Disease Drugs market size, 2024–2034, placeholder estimates. $1.31 Bn in 2024, $1.41 Bn in 2025 and $2.74 Bn in 2034, 7.6% CAGR.
China Retinal Disease Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

China Retinal Disease Drugs Market Dynamics

Market Growth Drivers

An ageing population, more people with diabetes and long-term conditions, better treatments and wider access to specialist care are driving the retinal Disease Drugs market.

Opportunity

Longer-acting treatments, home-based care and screening in emerging markets give the retinal Disease Drugs market room to grow.

Market Restraints

High costs of new treatments, specialist shortages, low awareness and limited reimbursement in some countries hold back the retinal Disease Drugs market.

Competitive Landscape for Retinal Disease Drugs Market in China

The retinal Disease Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Retinal Disease Drugs Market in China

Retinal Disease Drugs in China: rules, payment and research

Drugs need approval from the National Medical Products Administration (NMPA) before sale.⁠[1] Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List.⁠[2] ClinicalTrials.gov lists 55 studies on Retinal Disease Drugs that are recruiting, active or about to start in China.⁠[3]

[1] National Medical Products Administration. Checked 14 Nov 2026.

[2] National Healthcare Security Administration. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for retinal Disease Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in China.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Retinal Disease Drugs right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Retinal Disease Drugs in context

China compared

  • Health spending per person: 763 US$ per person (2023). World: 1,317 US$ per person (2023). 5th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 3.11 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 3rd highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 14.9% of people (2025). World: 10.4% of people (2025). 6th highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 17 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 17 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Retinal Disease Drugs market in China?
Placeholder estimate: about $1.41 Bn in 2025, rising to about $2.74 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Retinal Disease Drugs market in China growing?
Placeholder estimate: about 7.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Retinal Disease Drugs market report cover?
The report splits the market by drug (Aflibercept, Faricimab, Ranibizumab, Biosimilars), indication (Wet AMD, Diabetic Macular Edema, Retinal Vein Occlusion) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Retinal Disease Drugs market?
Key players include Regeneron Pharmaceuticals, Roche, Bayer AG, Novartis AG and Samsung Bioepis.
What is driving the Retinal Disease Drugs market?
An ageing population, more people with diabetes and long-term conditions, better treatments and wider access to specialist care are driving the retinal Disease Drugs market.
Who regulates Retinal Disease Drugs in China?
Drugs need approval from the National Medical Products Administration (NMPA) before sale. Source: National Medical Products Administration. Checked 14 Nov 2026.
How is healthcare paid for in China?
Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List. Source: National Healthcare Security Administration. Checked 14 Nov 2026.
How many clinical trials on Retinal Disease Drugs are running in China?
55 studies are recruiting, active or about to start in China, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.
How much research is published on Retinal Disease Drugs?
PubMed lists 1,099 papers on Retinal Disease Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in China

See all

Related on eye health

See the topic